Infant Bacterial Therapeutics AB senarelägger årsstämman
April 03, 2020 08:00 ET
|
Infant Bacterial Therapeutics AB
På grund av svårigheten att samlas i större grupper, orsakade av corona-epidemin, har IBT:s styrelse beslutat att skjuta årsstämman till den 16:e juni, 2020, istället för som planerat den 11:e maj,...
Infant Bacterial Therapeutics AB postpones Annual General Meeting
April 03, 2020 08:00 ET
|
Infant Bacterial Therapeutics AB
Due to the difficulty of gathering in larger groups, caused by the Corona Epidemic, IBT's Board of Directors has decided to postpone the Annual General Meeting until June 16, 2020, instead of the...
Infant Bacterial Therapeutics AB (publ) meddelar att valberedning inför årsstämman 2020 tillsatts
November 11, 2019 11:00 ET
|
Infant Bacterial Therapeutics AB
Årsstämman 2019 beslutade att valberedning skulle tillsättas enligt följande: ”Styrelsens ordförande ska sammankalla de tre till röstetalet största aktieägarna i bolaget, vilka äger utse varsin...
Infant Bacterial Therapeutics AB (publ) announces that the Nomination Committee is appointed for the Annual General Meeting 2020
November 11, 2019 11:00 ET
|
Infant Bacterial Therapeutics AB
The Annual General Meeting of 2019 decided that the Nomination Committee would be appointed as follows: “The Chairman of the Board shall convene the three largest shareholders in the Company, who each...
Lilian Wikström Ph.D. har begärt eget utträde från styrelsen i Infant Bacterial Therapeutics AB
November 05, 2019 11:00 ET
|
Infant Bacterial Therapeutics AB
Lilian Wikström Ph.D. har begärt sitt utträde ur styrelsen i IBT med omedelbar verkan på grund av risk för jäv som har uppstått i hennes roll som VD för KI Innovations AB. Styrelseordförande...
Lilian Wikström Ph.D. has requested to resign from the Board of Directors of Infant Bacterial Therapeutics AB
November 05, 2019 11:00 ET
|
Infant Bacterial Therapeutics AB
Lilian Wikström Ph.D. has requested to resign from the Board of Directors of IBT with immediate effect due to the risk of conflict of interest that has arisen in her role as CEO of KI Innovations AB. ...
Infant Bacterial Therapeutics har rekryterat den första patienten i den pivotala kliniska Fas III-studie
July 04, 2019 08:15 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics har rekryterat den första patienten i den pivotala kliniska Fas III-studie, The Connection Study. Utvecklingsprogrammet för IBP-9414, i vilken The Connection Study är den...
Infant Bacterial Therapeutics has recruited the first patient in the pivotal Phase III clinical study
July 04, 2019 08:15 ET
|
Infant Bacterial Therapeutics AB
IBT has recruited the first patient in the Phase III pivotal clinical study, The Connection Study. The development program for IBP-9414, of which The Connection Study is the final planned clinical...
FDA och Infant Bacterial Therapeutics överens rörande Fas III studiens utformning
May 19, 2019 14:00 ET
|
Infant Bacterial Therapeutics AB
IBT har under en längre tid rådgjort med den amerikanska läkemedelsmyndigheten FDA (US Food and Drug Administration) angående hur företagets planerade fas III studie skall utformas. FDA har nu i...
FDA and Infant Bacterial Therapeutics agree on the design of Phase III study
May 19, 2019 14:00 ET
|
Infant Bacterial Therapeutics AB
IBT has for an extended time consulted with the US Food and Drug Administration (FDA) on how the company's planned Phase III study should be designed. The FDA has now informed IBT in writing that IBT...